Gender diffrences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia

European Journal of Endocrinology

Volumn 148, Issue 3, 2003, Pages 325-331

  Colao, Annamaria ^a   Di Sarno, Antonella ^a   Cappabianca, Paolo ^a   Briganti, Francesco ^a   Pivonello, Rosario ^a   Di Somma, Carolina ^a   Faggiano, Antongiulio ^a   Biondi, Bernadette ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CORTISONE ACETATE; GROWTH HORMONE RELEASING FACTOR; LEVOTHYROXINE; PROLACTIN; VASOPRESSIN; ANTINEOPLASTIC AGENT; ERGOLINE DERIVATIVE; GALACTOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GALACTORRHEA; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; HYPOPITUITARISM; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROSPECTIVE STUDY; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; TUMOR VOLUME; VISUAL FIELD DEFECT; WEIGHT GAIN; BLOOD; FOLLOW UP; HYPOPHYSIS TUMOR; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT; TREATMENT OUTCOME; VISUAL FIELD;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ERGOLINES; FEMALE; FOLLOW-UP STUDIES; GALACTOSE; HUMANS; HYPERPROLACTINEMIA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; VISUAL FIELDS; WEIGHT GAIN;

EID: 0037356827     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480325     Document Type: Article

References (38)

1. Colao A & Lombardi G. Growth hormone and prolactin excess. Lancet 1998 352 1455-1461.
2. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C & Friesen HG. Prolactin-secreting tumors and hypogonadism in 22 men. New England Journal of Medicine 1978 299 847-852.
3. Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal of Endocrinology 1996 135 548-552.
4. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. European Journal of Endocrinology 1998 138 286-293.
5. Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT et al. Prolactinomas in male and female patients: a comparative clinico-pathology study. Mayo Clinic Proceedings 1998 73 1046-1052.
6. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS & Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. Journal of Clinical Endocrinology and Metabolism 2000 85 3053-3057.
7. Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107.
8. Colao A, Annunziato L & Lombardi G. Treatment of prolactinomas. Annals of Medicine 1998 30 452-459.
9. Molitch ME, Thorner MO & Wilson C. Management of prolactinomas. Journal of Clinical Endocrinology and Metabolism 1997 82 996-1000.
10. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. Journal of Clinical Endocrinology and Metabolism 1997 82 3574-3579.
11. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. Journal of Clinical Endocrinology and Metabolism 2000 85 2247-2252.
12. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R et al. Resistance to cabergoline as compared to bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism 2001 86 5256-5261.
13. Colao A, Cerbone G, Pivonello R, Aimaretti G, Loche S, Di Somma C et al. The growth hormone (GH) response to arginine plus GH releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism 1999 84 1277-1282.
14. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G et al. Bone loss is correlated to the severity of growth hormone (GH) deficiency in adult patients with hypopituitarism. Journal of Clinical Endocrinology and Metabolism 1999 84 1919-1924.
15. Cappabianca P, Lodrini S, Felisati G, Peca C, Cozzi R, Di Sarno A et al. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. Journal of Endocrinological Investigation 2001 24 183-187.
16. Somma M, Beauregard H & Rasio E. Le prolactinome chez l'homme: evaluation préopératoire de 40 patients. Neurochirurgie 1981 27 37-39.
17. Eversmann T, Eichinger R, Fahlbusch R, Rjosk HK & von Werder K. Die hyperprolaktinämie beim mann: klinik und therapie. Schweiz Medica Wochenschreibe 1981 111 1782-1789.
18. Spark RF, Wills CA, O'Reilly G, Ransil BJ & Bergland R. Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet 1982 2 129-132.
19. Hulting AL, Muhr C, Lundberg PO & Werner S. Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Medica Scandinavica 1985 217 101-109.
20. Walsh JP & Pullan PT. Hyperprolactinaemia in males: a heterogeneous disorder. Australian New Zealand Journal of Medicine 1997 27 385-390.
21. Grisoli F, Vincentelli F, Jaquet P, Guibout M, Hassoun J & Farnarier P. Prolactin secreting adenoma in 22 men. Surgical Neurology 1980 13 241-247.
22. Berezin M, Shimon I & Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). Journal of Endocrinological Investigation 1995 18 436-441.
23. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G et al. Bone density and bone marker responses to dopamine agonist therapy in hyperprolactinemia males. Journal of Clinical Endocrinology and Metabolism 1998 83 807-813.
24. Verhelst J, Abs R, Maiter D, Vandeweghe M, Velkeniers B, Mockel J et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2518-2522.
25. Lachelin GCL, Abu-Fadil S & Yen SSC. Functional delineation of hyperprolactinaemic amenorrhea. Journal of Clinical Endocrinology and Metabolism 1997 44 1163-1174.
26. Nunes MCP, Sobrinho LG, Calhaz-Jorge C, Santos MA, Mauricio JC & Sousa MF. Psychosomatic factors in patients with hyperprolactinaemia and/or galactorrhea. Obstetrics and Gynecology 1980 55 591-595.
27. Cohen LM, Greenberg DB & Murray GB. Neuropsychiatric presentation of men with pituitary tumors (the 'four As'). Psychosomatics 1984 25 925-928.
28. Creemers LB, Zelissen PMJ, van't Verlaat JW & Koppeschaar HPF. Prolactinoma and body weight: a retrospective study. Acta Endocrinologica 1991 125 392-396.
29. Delgrange E, Donckier J & Maiter D. Hyperprolactinemia as a reversible cause of weight gain in male patients? Clinical Endocrinology 1999 50 271-272.
30. Greenman Y, Torjman K & Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clinical Endocrinology 1998 48 547-553.
31. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo GF, Merola B et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 876-883.
32. Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Journal of Clinical Endocrinology and Metabolism 1996 81 2338-2343.
33. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. Journal of Clinical Endocrinology and Metabolism 1998 83 2777-2780.
34. Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A & Trimarchi F. A first choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation 1999 22 354-359.
35. Delgrange E, Maiter D, Donckier J & Tourniaire J. Influence of age on the clinical presentation of prolactinomas in male patients. Gerontology 1999 45 160-164.
36. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. New England Journal of Medicine 1994 331 904-909.
37. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical Endocrinology 1997 46 409-413.
38. Muratori M, Arosio M, Gambino G, Romano C, Biella O & Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation 1997 20 537-546.